(Reuters) – AbbVie Inc said on Wednesday it expects first-quarter earnings to be hit by acquired in-process research and development (IPR&D) and milestones expenses.
The company expects first-quarter adjusted earnings, including the impact of acquired IPR&D and milestones expense, to be between $2.31 per share and $2.41 per share.
(Reporting by Arunima Kumar in Bengaluru; Editing by Sriraj Kalluvila)
